AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, was awarded an $855,000,000 modification (P00005) to contract W911QY-20-C-0119 for the manufacture, distribution and storage of AZD7442, known as Evusheld, to treat COVID-19 in the general population. Work will be performed in various locations, with an estimated completion date of March 31, 2023. Health and Human Services Biomedical Advanced Research and Development Authority (HHS BARDA) Coronavirus Aid, Relief and Economics Security Act funds in the amount of $405,300,000; and HHS BARDA American Rescue Plan Act funds in the amount of $449,700,000, were obligated at the time of the award. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity.